AQUA07 vs Ensartinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline
AQUA07
Developed by Chugai Pharma
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2030 · NCT07617337 (registry estimate)
No aligned efficacy figure on record for this race.
Ensartinib · Ensacove
Marketed by Xcovery Holdings and partners
NCT02767804 · Phase 3 · active, not recruiting
This was a randomized, phase 3, active-controlled trial with 290 patients comparing ensartinib to crizotinib, using progression-free survival (a hard clinical endpoint) as the primary measure, and the trial met its primary endpoint with a large, statistically significant improvement favoring ensartinib. However, the study was open-label (no blinding of patients or investigators), which limits confidence in outcome assessments despite the use of independent radiology review, so the evidence is graded as solid but not the highest tier.
Next expected readout: February 2027 · NCT05241028 (registry estimate)
Reported efficacy
Progression-free survival (PFS) (36 months): eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001. (met)
Result source: NCT02767804
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | AQUA07 | Ensartinib |
|---|---|---|
| PFS, median | —Not reported | —Trial running · NCT06955325 |
| OS, median | —Not reported | —Trial running · NCT06955325 |
| ORR | —Not reported | —Trial running · NCT06955325 |
| Duration of response, median | —Not reported | —Trial running · NCT06955325 |
PFS, median
- AQUA07
- —Not reported
- Ensartinib
- —Trial running · NCT06955325
OS, median
- AQUA07
- —Not reported
- Ensartinib
- —Trial running · NCT06955325
ORR
- AQUA07
- —Not reported
- Ensartinib
- —Trial running · NCT06955325
Duration of response, median
- AQUA07
- —Not reported
- Ensartinib
- —Trial running · NCT06955325
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
AQUA07: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. AQUA07: 0 of 4 rows · Ensartinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ensartinib |
|---|---|
| Dropout rate | 0%225 mga NCT01625234 · Phase 1/2 show 7 more results0%225 mg NCT01625234 · Phase 1/2 0%250 mg NCT01625234 · Phase 1/2 0%200 mg NCT01625234 · Phase 1/2 0%100 mg NCT01625234 · Phase 1/2 0%50 mg NCT01625234 · Phase 1/2 0%25 mg NCT01625234 · Phase 1/2 n/a: no completion milestone200 mg NCT02898116 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —225 mga NCT01625234 · Phase 1/2 show 7 more results—225 mg NCT01625234 · Phase 1/2 —250 mg NCT01625234 · Phase 1/2 —200 mg NCT01625234 · Phase 1/2 —100 mg NCT01625234 · Phase 1/2 —50 mg NCT01625234 · Phase 1/2 —25 mg NCT01625234 · Phase 1/2 50%200 mg NCT02898116 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 50%225 mga NCT01625234 · Phase 1/2 show 7 more results43.6%225 mg NCT01625234 · Phase 1/2 50%250 mg NCT01625234 · Phase 1/2 54.5%200 mg NCT01625234 · Phase 1/2 40%100 mg NCT01625234 · Phase 1/2 33.3%50 mg NCT01625234 · Phase 1/2 25%25 mg NCT01625234 · Phase 1/2 50%200 mg NCT02898116 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | show 7 more results200 mg hypoalbuminaemia 100% anaemia 50% arthralgia 50% NCT02898116 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ensartinib
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AQUA07's landscape · Ensartinib's landscape